# OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
Canonical URL: https://biopharmsignal.com/news/OSUR/orasure-technologies-inc-announces-fda-clearance-that-expands-patient-friendly-access-to-testing-for-sexually-transmitted-infections
Ticker: OSUR
Company: OraSure Technologies, Inc.
Source: OraSure Technologies, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://orasure.gcs-web.com
## Summary

The clearance combines OraSure’s Colli-Pee™•Dx Urine Collection Kit for at-home sample collection with Roche’s cobas® molecular lab testing equipment BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home

## Article Body
The clearance combines OraSure’s Colli-Pee™•Dx Urine Collection Kit for at-home sample collection with Roche’s cobas® molecular lab testing equipment BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home
## Recent Company News
- 2026-06-25 13:46 EST — [OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections](https://biopharmsignal.com/news/OSUR/orasure-technologies-inc-announces-fda-clearance-that-expands-patient-friendly-access-to-testing-for-sexually-transmitted-infections) — Source: OraSure Technologies, Inc.
- 2026-06-25 13:46 EST — [OraSure Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/OSUR/orasure-announces-first-quarter-2026-financial-results) — Source: OraSure Technologies, Inc.
- 2026-06-25 13:46 EST — [OraSure to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/OSUR/orasure-to-participate-in-upcoming-investor-conference) — Source: OraSure Technologies, Inc.
- 2026-06-25 13:46 EST — [OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates](https://biopharmsignal.com/news/OSUR/orasure-technologies-issues-statement-regarding-altai-capital-s-intent-to-nominate-director-candidates) — Source: OraSure Technologies, Inc.
- 2026-06-25 13:46 EST — [OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review](https://biopharmsignal.com/news/OSUR/orasure-submits-ct-ng-molecular-self-test-and-colli-peetm-urine-collection-device-for-fda-review) — Source: OraSure Technologies, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)